ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range
Key Highlights
- ➤Q3 revenue $560.4 million, up from $537.0 million year over year
- ➤Q3 adjusted diluted EPS $2.44, versus $2.03 last year
- ➤Q3 GAAP net income $26.8 million, reversing prior-year $3.4 million loss
- ➤Infusion Systems revenue $192.5 million, up $18.6 million year over year
- ➤2026 guidance reaffirmed, with results expected toward the high end of ranges
Expert Statements
Vivek Jain, Chief Executive Officer of ICU Medical
“Third quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business.”
SAN CLEMENTE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2026.
Third quarter 2026 GAAP revenue was $560.4 million, as compared to $537.0 million in the same period in the prior year. GAAP gross profit for the third quarter of 2026 was $234.8 million, as compared to $200.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2026 was 42%, as compared to 37% in the same period in the prior year. GAAP net income for the third quarter of 2026 was $26.8 million, or $1.07 per diluted share, as compared to GAAP net loss of $(3.4) million, or $(0.14) per diluted share, for the third quarter of 2025. Adjusted diluted earnings per share for the third quarter of 2026 was $2.44 as compared to $2.03 for the third quarter of 2025. Adjusted EBITDA was $113.9 million for the third quarter of 2026 as compared to $105.9 million for the third quarter of 2025.
Get started
Create a free account to read the full story.